Progress in the use of type I interferon blockade in systemic lupus erythematosus
{{output}}
Introduction: The successful clinical trials of the type I interferon (IFN) receptor monoclonal antibody, anifrolumab, have proven the benefit of IFN blockade in systemic lupus erythematosus (SLE), and paved the way for novel the... ...
